Table 1.

The FDA-approved and clinically developed RAS inhibitors in cancer therapies

Target	Drug	Highest Phase	Indications	Company/Identifier	Status
Farnesyltr-ansferase	Tipifarnib	Approved	Head and neck squamous cell carcinoma harboring HRAS mutations who have progressed following platinum-containing chemotherapy	Kura Oncology	/
	Lonafarnib (SCH66336)	Approved	Hutchinson-Gilford progeria syndrome and progeroid laminopathies	Merck & Co	/
		III	Carcinoma, non-small cell lung, metastases, neoplasm	NCT00050336	Terminated
		III	Myelodysplastic syndromes, leukemia, myelomonocytic, chronic, myelodysplasia, myelomonocytic	NCT00109538	Terminated
	Salirasib	II	Non-small cell lung cancer	NCT00531401	Completed
SOS	BI-1701963	II	Advanced solid tumors, KRASG12C mutation	NCT04185883	Recruiting
	MRTX0902	I/II	Solid tumor, advanced solid tumor, non-small cell lung cancer, colorectal cancer	NCT05578092	Recruiting
SHP2	RMC-4630	II	Non-small cell lung cancer	NCT05054725	Active, not recruiting
		I/II	Solid tumor	NCT03989115	Completed
		I/II	Advanced solid tumors, KRASG12C mutation	NCT04185883	Recruiting
		I/II	Metastatic neoplasm	NCT04418661	Active, not recruiting
	TNO155	I/II	KRASG12C mutant solid tumors, non-small cell lung, carcinoma, colorectal, lung cancer, pulmonary cancer	NCT04699188	Recruiting
		I/II	Advanced cancer, metastatic cancer, malignant neoplastic disease	NCT04330664	Active, not recruiting
		I/II	Advanced solid tumors, KRASG12C mutation	NCT04185883	Recruiting
	RLY-1971	I	Advanced solid tumors, metastatic solid tumors	NCT05487235	Recruiting
		I	Solid tumor, unspecified, adult	NCT04252339	Completed
		I	Colorectal cancer, non-small cell lung cancer	NCT05954871	Recruiting
KRASG12C	Adagrasib (MRTX849)	Approved	Solid tumors harboring KRASG12C oncogenic driver mutation, including non-small cell lung cancer and colorectal cancer	Mirati Therapeutics	/
	Sotorasib (AMG510)	Approved	KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer	Amgen	/
	JNJ-74699157 (ARS-3248)	I	Neoplasms, advanced solid tumors, non-small cell lung cancer, colorectal cancer	NCT04006301	Completed
	Divarasib (GDC-6036)	III	Non-small cell lung cancer	NCT03178552	Recruiting
	D-1553	II	Non-small cell lung cancer	NCT05383898	Recruiting
		II	Non-small cell lung cancer	NCT05492045	Recruiting
		II	Solid tumor, non-small cell lung cancer, colorectal cancer	NCT04585035	Recruiting
		II	Solid tumor	NCT05379946	Not yet recruiting
	JDQ443	III	Non-small cell lung cancer	NCT05132075	Recruiting
	RMC-6291	I	Non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, advanced solid tumor	NCT05462717	Recruiting
Non-KRASG12C	MRTX1133	I/II	Solid tumor, advanced solid tumor, non-small cell lung cancer, colorectal cancer, pancreatic adenocarcinoma	NCT05737706	Recruiting
	RMC-6236	I	Non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, advanced solid tumors	NCT05379985	Recruiting
siRNA strategies	KRASG12D iExosomes	I	KRASG12D metastatic pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma	NCT03608631	Recruiting
Antisense oligonucleotide	AZD4785	I	Non-small cell lung cancer, advanced solid tumors	NCT03101839	Completed
RAS analog	Rigosertib	III	Metastatic pancreatic adenocarcinoma	NCT01360853	Completed
		III	Myelodysplastic syndromes, chronic myelomonocytic leukemia	NCT01928537	Completed
		III	Myelodysplastic syndromes, chronic myelomonocytic leukemia	NCT01241500	Completed
Cancer vaccines	mRNA-5671	I	Non-small cell lung cancer pancreatic cancer, colorectal cancer	NCT03948763	Completed
Antibody	NS1	II	Hematologic malignancy, acute leukemia, acute myeloid leukemia, acute lymphoblastic	NCT05735717	Recruiting

Source: All the information is derived from ClinicalTrials.gov (https://www.clinicaltrials.gov) and the United States Food and Drug Administration.gov (https://www.fda.gov/)